A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients
Background: Several driver genetic alterations have been identified in micropapillary lung adenocarcinoma (MPA). However, the frequency of ROS1 rearrangements is yet unclear. Herein, we investigated the associations between clinicopathological and molecular characteristics of MPA compared with non-micropapillary lung adenocarcinoma (LA).
Methods: FFPE sections derived from lung adenocarcinoma patients who never received adjuvant chemotherapy or radiation therapy prior to surgical resection were collected from October 2016 to June 2019. EGFR mutations, ROS1 rearrangements and EML4-ALK fusions were identified in a set of 131 MPA and LA cases by using the Amplification Refractory Mutation System.
Results: EGFR mutations had occurred in 42 (76.4%) MPA patients and 42 (55.3%) LA patients. But interestingly, ROS1 rearrangement was present in 10.9% (6/55) MPA cases and 1.3% (1/76) LA cases. Moreover, 7.3% (4/55) MPA samples had multiple gene mutations, while only 1.3% (1/76) LA cases had double gene alterations.
Conclusions: A higher prevalence of ROS1 rearrangements or combined mutations of ROS1 and EGFR or EML4-ALK may play a critical role in the tumorigenesis of MPA. These finding provides a novel therapy strategy for the patients with malignant MPA through combining TKIs than one TKI.
Figure 1
On 16 Jul, 2020
On 02 Jul, 2020
On 29 Jun, 2020
On 28 Jun, 2020
On 28 Jun, 2020
On 20 Jun, 2020
Received 19 Jun, 2020
On 15 Jun, 2020
On 15 Jun, 2020
Received 15 Jun, 2020
On 14 Jun, 2020
Invitations sent on 14 Jun, 2020
On 13 Jun, 2020
On 13 Jun, 2020
Posted 24 Feb, 2020
On 22 May, 2020
Received 21 May, 2020
Received 09 May, 2020
On 27 Mar, 2020
On 21 Mar, 2020
On 09 Mar, 2020
Invitations sent on 21 Feb, 2020
On 19 Feb, 2020
On 18 Feb, 2020
On 18 Feb, 2020
On 17 Feb, 2020
A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients
On 16 Jul, 2020
On 02 Jul, 2020
On 29 Jun, 2020
On 28 Jun, 2020
On 28 Jun, 2020
On 20 Jun, 2020
Received 19 Jun, 2020
On 15 Jun, 2020
On 15 Jun, 2020
Received 15 Jun, 2020
On 14 Jun, 2020
Invitations sent on 14 Jun, 2020
On 13 Jun, 2020
On 13 Jun, 2020
Posted 24 Feb, 2020
On 22 May, 2020
Received 21 May, 2020
Received 09 May, 2020
On 27 Mar, 2020
On 21 Mar, 2020
On 09 Mar, 2020
Invitations sent on 21 Feb, 2020
On 19 Feb, 2020
On 18 Feb, 2020
On 18 Feb, 2020
On 17 Feb, 2020
Background: Several driver genetic alterations have been identified in micropapillary lung adenocarcinoma (MPA). However, the frequency of ROS1 rearrangements is yet unclear. Herein, we investigated the associations between clinicopathological and molecular characteristics of MPA compared with non-micropapillary lung adenocarcinoma (LA).
Methods: FFPE sections derived from lung adenocarcinoma patients who never received adjuvant chemotherapy or radiation therapy prior to surgical resection were collected from October 2016 to June 2019. EGFR mutations, ROS1 rearrangements and EML4-ALK fusions were identified in a set of 131 MPA and LA cases by using the Amplification Refractory Mutation System.
Results: EGFR mutations had occurred in 42 (76.4%) MPA patients and 42 (55.3%) LA patients. But interestingly, ROS1 rearrangement was present in 10.9% (6/55) MPA cases and 1.3% (1/76) LA cases. Moreover, 7.3% (4/55) MPA samples had multiple gene mutations, while only 1.3% (1/76) LA cases had double gene alterations.
Conclusions: A higher prevalence of ROS1 rearrangements or combined mutations of ROS1 and EGFR or EML4-ALK may play a critical role in the tumorigenesis of MPA. These finding provides a novel therapy strategy for the patients with malignant MPA through combining TKIs than one TKI.
Figure 1